{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:03:57Z","timestamp":1791576237719,"version":"4.3.4"},"reference-count":39,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boehringer-Ingelheim","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy persistence depending on NOAC dosing regimen (once daily (QD) vs. twice daily (BID)). Methods: Consecutive patients were followed for 1 year in phase III of the GLORIA-AF registry. Drug persistence was defined as the use of OAC without any discontinuation in &gt;30 days or switching to alternative therapy. Results: Among 21,109 eligible patients in phase III, 17,266 patients who were prescribed OAC at baseline and those who took \u22651 OAC dose were included. The 1-year proportion of patients receiving NOAC and VKA who persisted on treatment was 80% and 75%, respectively. The 1-year persistence with NOACs BID and NOACs QD was 81% and 80%, respectively. Female gender, hypertension, older age, alcohol use, permanent, asymptomatic, and minimally symptomatic AF were associated with better OAC persistence. Region, medication usage predisposing to bleeding, being a current smoker, treatment reimbursement, and proton pump inhibitors were associated with lower OAC persistence. Conclusions: Drug persistence was higher with NOACs (1-year persistence was 80%) than with VKAs (75%). There was little difference in 1-year persistence between NOAC dosing regimens.<\/jats:p>","DOI":"10.3390\/jcm9061969","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T08:54:50Z","timestamp":1592988890000},"page":"1969","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-1975","authenticated-orcid":false,"given":"Monika","family":"Kozie\u0142","sequence":"first","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool L7 8TX, UK"},{"name":"1st Department of Cardiology and Angiology, Silesian Centre for Heart Diseases, 41-800 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Mazurek","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology and Angiology, Silesian Centre for Heart Diseases, 41-800 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-2876","authenticated-orcid":false,"given":"Christine","family":"Teutsch","sequence":"additional","affiliation":[{"name":"Department of Clinical Development and Medical Affairs, Therapeutic Area Cardiometabolism, Boehringer Ingelheim International GmbH, 55216 Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, 45133 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-9225","authenticated-orcid":false,"given":"Sergio J.","family":"Dubner","sequence":"additional","affiliation":[{"name":"Cl\u00ednica y Maternidad Suizo Argentina, Buenos Aires C1420, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Sheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Cardiology Department, Atrial Fibrillation Center, Beijing AnZhen Hospital, Capital Medical University,  Beijing 100011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Rothman","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, NC 27709, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9145-6887","authenticated-orcid":false,"given":"Axel","family":"Brandes","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miney","family":"Paquette","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boehringer Ingelheim,  Burlington, ON 05401, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Zint","sequence":"additional","affiliation":[{"name":"Global Epidemiology Department, Boehringer Ingelheim International GmbH, 55216 Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel Riou","family":"Fran\u00e7a","sequence":"additional","affiliation":[{"name":"Global Epidemiology Department, Boehringer Ingelheim International GmbH, 55216 Ingelheim am Rhein, Germany"},{"name":"Sanofi-Aventis Recherche et Development, 91380 Chilly-Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7209-5075","authenticated-orcid":false,"given":"Shihai","family":"Lu","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Sciences Department, Boehringer Ingelheim Pharmaceuticals, Inc.,  Ridgefield, CT 06877, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee B.","family":"Bartels","sequence":"additional","affiliation":[{"name":"Global Epidemiology Department, Boehringer Ingelheim International GmbH, 55216 Ingelheim am Rhein, Germany"},{"name":"Hannover Medical School, 30159 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1423-5348","authenticated-orcid":false,"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis, Leiden University Medical Center, 1043 AJ Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool L7 8TX, UK"},{"name":"1st Department of Cardiology and Angiology, Silesian Centre for Heart Diseases, 41-800 Zabrze, Poland"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, 9000 Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillationast, present and future. Comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report","volume":"154","author":"Lip","year":"2018","journal-title":"CHEST"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2017.07.793","article-title":"Persistence With Dabigatran Therapy at 2 Years in Patients with Atrial Fibrillation","volume":"70","author":"Paquette","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/europace\/euu311","article-title":"Non-vitamin K antagonist oral anticoagulants: Considerations on once- vs. twice-daily regimens and their potential impact on medication adherence","volume":"17","author":"Vrijens","year":"2015","journal-title":"Europace"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ahj.2013.12.006","article-title":"Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation","volume":"167","author":"Huisman","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"CHEST"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"CHEST"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun. Stat. Simul. Comput."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10654-016-0158-2","article-title":"Disengaging from statistical significance","volume":"31","author":"Rothman","year":"2016","journal-title":"Eur. J. Epidemiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/aje\/kwq198","article-title":"Treatment effects in the presence of unmeasured confounding: Dealing with observations in the tails of the propensity score distribution\u2014A simulation study","volume":"172","author":"Rothman","year":"2010","journal-title":"Am. J. Epidemiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: Issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1468794110362874","article-title":"Benefits of \u201cObserver Effects\u201d: Lessons from the Field","volume":"10","author":"Monahan","year":"2010","journal-title":"Qual. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1160\/TH15-04-0350","article-title":"Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study","volume":"115","author":"Martinez","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/CIRCOUTCOMES.113.000192","article-title":"Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin","volume":"6","author":"Zalesak","year":"2013","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/03007995.2014.907140","article-title":"Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients","volume":"30","author":"Laliberte","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1185\/03007995.2014.933577","article-title":"Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation","volume":"30","author":"Nelson","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.12659\/MSM.915875","article-title":"Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry","volume":"25","author":"Liu","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/jth.12241","article-title":"Adherence to anticoagulant treatment with dabigatran in a real-world setting","volume":"11","author":"Schulman","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijcard.2016.03.051","article-title":"Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States","volume":"212","author":"Coleman","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.joa.2015.04.004","article-title":"Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study","volume":"31","author":"Shiga","year":"2015","journal-title":"J. Arrhythm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/heartjnl-2016-310672","article-title":"Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation","volume":"103","author":"Jackevicius","year":"2017","journal-title":"Heart"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e004517","DOI":"10.1161\/JAHA.116.004517","article-title":"Major Bleeding Complications and Persistence with Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients","volume":"6","author":"Lamberts","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-015-1983-z","article-title":"Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation","volume":"72","author":"Forslund","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_28","first-page":"113","article-title":"Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation","volume":"109","author":"Cataldo","year":"2018","journal-title":"Recenti. Prog. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1185\/03007995.2015.1096242","article-title":"Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure","volume":"31","author":"McHorney","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1185\/03007995.2015.1077213","article-title":"Pharmacy quality alliance measure: Adherence to non-warfarin oral anticoagulant medications","volume":"31","author":"Crivera","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.clinthera.2016.09.014","article-title":"Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation","volume":"38","author":"McHorney","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ehjcvp\/pvw048","article-title":"Adherence with oral anticoagulation in non-valvular atrial fibrillation: A comparison of vitamin K antagonists and non-vitamin K antagonists","volume":"3","author":"Nielsen","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1055\/s-0039-1697954","article-title":"NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters?","volume":"120","author":"Hwang","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1055\/s-0039-1683428","article-title":"Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study","volume":"119","author":"Hohnloser","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_35","first-page":"e22","article-title":"Effect of medication dosing frequency on adherence in chronic diseases","volume":"15","author":"Saini","year":"2009","journal-title":"Am. J. Manag. Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s12325-012-0040-x","article-title":"Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients","volume":"29","author":"Laliberte","year":"2012","journal-title":"Adv. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/europace\/euu319","article-title":"Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry","volume":"17","author":"Ebertz","year":"2015","journal-title":"Europace"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1055\/s-0038-1676835","article-title":"Improving the Prescription of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review","volume":"119","author":"Pritchett","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/CIRCULATIONAHA.118.038635","article-title":"Biomarkers for Prediction of Stroke and Bleeds in Atrial Fibrillation","volume":"139","author":"Hylek","year":"2019","journal-title":"Circulation"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/6\/1969\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:41:58Z","timestamp":1760175718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/6\/1969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["jcm9061969"],"URL":"https:\/\/doi.org\/10.3390\/jcm9061969","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]}}}